Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study

被引：5
作者：
Soto, Caitlin L. [1 ]
Hsu, Alice J. [1 ]
Lee, Jae Hyoung [2 ]
Dzintars, Kathryn [1 ]
Choudhury, Rebecca [3 ]
Jenkins, Timothy C. [4 ]
Mccreary, Erin K. [5 ]
Quartuccio, Katelyn S. [6 ]
Stohs, Erica J. [7 ]
Zimmerman, Matty [1 ]
Tamma, Pranita D. [2 ,8 ]
机构：
[1] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD USA
[2] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21287 USA
[3] Montefiore Med Ctr, Dept Med, Bronx, NY USA
[4] Denver Hlth, Dept Med, Denver, CO USA
[5] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA USA
[6] Univ Rochester, Med Ctr, Dept Pharm, Rochester, NY 14627 USA
[7] Univ Nebraska, Dept Med, Med Ctr, Omaha, NE USA
[8] Johns Hopkins Univ, Dept Pediat, Sch Med, 200 North Wolfe St,Rubinstein Bldg,Rm 3149, Baltimore, MD 21287 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2024年 / 78卷 / 01期
关键词：
carbapenem-resistant Enterobacterales; bacteremia; ceftazidime-avibactam; meropenem-vaborbactam;
D O I：
10.1093/cid/ciad476
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
In a propensity-score-weighted cohort of 183 adults with carbapenem-resistant Enterobacterales bacteremia at 24 US hospitals, patients receiving short courses of active therapy (7-10 days, median 9 days) experienced similar odds of recurrent bacteremia or death within 30 days as those receiving prolonged courses of active therapy (14-21 days, median 14 days).
引用
收藏
页码：27 / 30
页数：4
相关论文
共 50 条
  • [21] Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data
    Clancy, Cornelius J.
    Potoski, Brian A.
    Buehrle, Deanna
    Nguyen, M. Hong
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (08):
  • [22] High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections A retrospective cohort study
    Geng, Ting-Ting
    Xu, Xin
    Huang, Man
    MEDICINE, 2018, 97 (08)
  • [23] Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
    King, Madeline
    Heil, Emily
    Kuriakose, Safia
    Bias, Tiffany
    Huang, Vanthida
    El-Beyrouty, Claudine
    McCoy, Dorothy
    Hiles, Jon
    Richards, Lynette
    Gardner, Julianne
    Harrington, Nicole
    Biason, Kenneth
    Gallagher, Jason C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (07)
  • [24] Risk factors of Carbapenem-resistant Enterobacterales intestinal colonization for subsequent infections in hematological patients: a retrospective case-control study
    Wang, Zihan
    Shao, Chunhong
    Shao, Jing
    Hao, Yingying
    Jin, Yan
    FRONTIERS IN MICROBIOLOGY, 2024, 15
  • [25] Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases
    Zhen, Sisi
    Zhao, Yuanqi
    Chen, Zhangjie
    Zhang, Tingting
    Wang, Jieru
    Jiang, Erlie
    Zhang, Fengkui
    Mi, Yingchang
    Zhu, Xiaofan
    Han, Mingzhe
    Xiao, Zhijian
    Wang, Jianxiang
    Feng, Sizhou
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [26] Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
    Alosaimy, Sara
    Lagnf, Abdalhamid M.
    Morrisette, Taylor
    Scipione, Marco R.
    Zhao, Jing J.
    Jorgensen, Sarah C. J.
    Mynatt, Ryan
    Carlson, Travis J.
    Jo, Jinhee
    Garey, Kevin W.
    Allen, David
    DeRonde, Kailynn
    Vega, Ana D.
    Abbo, Lilian M.
    Venugopalan, Veena
    Athans, Vasilios
    Saw, Stephen
    Claeys, Kimberly C.
    Miller, Mathew
    Molina, Kyle C.
    Veve, Michael
    Kufel, Wesley D.
    Amaya, Lee
    Yost, Christine
    Ortwine, Jessica
    Davis, Susan L.
    Rybak, Michael J.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (08):
  • [27] A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections
    Luterbach, Courtney L.
    Qiu, Hongqiang
    Hanafin, Patrick O.
    Sharma, Rajnikant
    Piscitelli, Joseph
    Lin, Feng-Chang
    Ilomaki, Jenni
    Cober, Eric
    Salata, Robert A.
    Kalayjian, Robert C.
    Watkins, Richard R.
    Doi, Yohei
    Kaye, Keith S.
    Nation, Roger L.
    Bonomo, Robert A.
    Landersdorfer, Cornelia B.
    van Duin, David
    Rao, Gauri G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (10)
  • [28] Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales
    Arboleda, Daniel
    Buitrago, Camilo
    Vergara, Erika Paola
    Nocua-Baez, Laura Cristina
    Saavedra, Carlos Humberto
    Cortes, Jorge Alberto
    ANTIBIOTICS-BASEL, 2025, 14 (03):
  • [29] Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study
    Yuan, Qing
    Guo, Lei
    Li, Bin
    Zhang, Sheng
    Feng, Haiting
    Zhang, Yan
    Yu, Meihong
    Hu, Hangbin
    Chen, Hongchao
    Yang, Qing
    Qu, Tingting
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [30] A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting
    Aslan, Abdullah Tarik
    Kirbas, Ekin
    Sancak, Banu
    Tanriverdi, Elif Seren
    Otlu, Baris
    Gursoy, Nafia Canan
    Yilmaz, Yakut Akyon
    Tozluyurt, Abdullah
    Liste, Umran
    Bicakcigil, Asiye
    Hazirolan, Gulsen
    Dag, Osman
    Guven, Gulay Sain
    Akova, Murat
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (04)
12345